发明名称 TREATMENT OF METASTIC BREAST CANCER
摘要 The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
申请公布号 US2017029527(A1) 申请公布日期 2017.02.02
申请号 US201615293165 申请日期 2016.10.13
申请人 Genentech, Inc. 发明人 Paton Virginia;Blackwood Chirchir Anne;Klein Pam
分类号 C07K16/30;A61K39/395;C07K16/28;A61K31/337;A61K45/06 主分类号 C07K16/30
代理机构 代理人
主权项 1. A method for the treatment of breast cancer, comprising administering to a HER2 positive metastatic breast cancer patient an effective amount of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody, and a taxane, wherein the patient did not receive prior chemotherapy or biologic therapy for their metastatic breast cancer.
地址 South San Francisco CA US